Abstract
CRISPR-based molecular detection has shown great potential for early cancer diagnostics and infectious disease testing at the point of care. Here, we investigated the effect of extending the 5′ end of CRISPR RNA (crRNA) on CRISPR detection and developed a 5′ eNd EXTension CRISPR (termed “NEXT CRISPR”) biosensing platform for rapid, highly sensitive, and specific nucleic acid detection. By taking advantage of a 5′ end-extended crRNA and optimized CRISPR reaction system, we demonstrated an enhanced NEXT CRISPR detection. The NEXT CRISPR is compatible with recombinase polymerase amplification (RPA), and can be easily adapted for both fluorescence detection and lateral flow strip readout. To enable point-of-care testing, we coupled RPA/NEXT CRISPR with a lateral flow assay to develop a NEXT CRISPR biosensing platform for human papillomavirus (HPV) 16 DNA detection with attomolar sensitivity within 30 min. Further, we clinically validated our NEXT CRISPR biosensing platform by detecting clinical swab samples, achieving a comparable performance with the conventional PCR method. This rapid, sensitive, and affordable NEXT CRISPR biosensing platform provides a promising tool for point-of-care diagnostics of cancers and infectious diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
